arrow_back
Medical Information
  • GILEAD and the GILEAD logo are trademarks of Gilead Sciences, Inc. KITE and the KITE logo are trademarks of Kite Pharma, Inc. © 2023 Gilead Sciences, Inc. All rights reserved. US-UNBP-2480 12/23

Breast research.

There is a 1 in 8 chance a woman develops breast cancer in her lifetime. In the U.S. alone, it is estimated ~298,000 women will be diagnosed with breast cancer each year. Breast cancer can be broken up into several subtypes based on the presence of hormone or HER2 receptors. Treatment for patients with breast cancer varies based on the specific subtype the patient is diagnosed with.1,2

Research commitment
Clinical trials in progress
Scientific focus

Committed to patients living with breast cancer

Select a trial below to view additional details (trial brochure or clinicaltrials.gov)
Timeline is based on trial start dates.
The safety and efficacy of these investigational agents and/or uses have not been established. There is no guarantee that they will become commercially available.

2020
EVER-132-002†

2L+ HR+/HER2- mBC

2021
ASCENT-J02

2L+ mTNBC

 
ELEVATE TNBC

1-2L mTNBC

2022
ASCENT-03

1L mTNBC, PD-L1-

 
ASCENT-04a

1L mTNBC, PD-L1+

 
ASCENT-05b

Adjuvant TNBC

2023
ASCENT-07

HR+/HER2- chemo-naïve mBC

00

Clinical trials in progress

Breast clinical trials actively recruiting.

Rollover trial for links to trial brochures and/or clinicaltrials.gov records.

The safety and efficacy of these investigational agents and/or uses have not been established. There is no guarantee that they will become commercially available.

1-2L mTNBC
Phase 2, open-label study evaluating the safety and efficacy of magrolimab in combination with nab-pacitaxel/paclitaxel or sacituzumab govitecan in patients with metastatic or locally advanced, unresectable TNBC
TNBC

ELEVATE TNBC

1L mTNBC, PD-L1–
Phase 3 randomized, open-label study of sacituzumab govitecan versus treatment of physician’s choice in patients with previously untreated, locally advanced, inoperable, or mTNBC whose tumors do not express PD-L1 or in patients previously treated with anti-PD(L)1 agents in the early setting whose tumors do express PD-L1
TNBC

ASCENT-03

1L mTNBC, PD-L1+
Phase 3 randomized, open-label study of sacituzumab govitecan and pembrolizumab versus treatment of physician’s choice and pembrolizumab in patients with previously untreated, locally advanced inoperable or mTNBC whose tumors express PD-L1
TNBC

ASCENT-04a

Adjuvant TNBC
Phase 3 randomized, open-label study of adjuvant sacituzumab govitecan and pembrolizumab versus treatment of physician’s choice in patients with TNBC who have residual invasive disease after surgery and neoadjuvant therapy
TNBC

ASCENT-05b

HR+/HER2- chemo-naïve mBC
Phase 3 randomized, open-label study of sacituzumab govitecan versus treatment of physician’s choice in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2 negative (HER2–) (HER2 IHC0 or HER2-low [IHC 1+, IHC2+/ISH-]) inoperable, locally advanced, or metastatic breast cancer and have received endocrine therapy
HR+/HER2- mBC

ASCENT-07

Scientific focus

The safety and efficacy of these investigational agents and/or uses have not been established. There is no guarantee that they will become commercially available.
MoAs in research
sacituzumab govitecan-hziy


Swipe left to view our late-stage asset mechanism of action video(s) that our trials are investigating in Breast Cancer treatment.

Clinicaltrials.gov may not reflect the most up-to-date information on the trials shown.

aIn collaboration with Merck. bIn collaboration with Alliance Foundation Trials, LLC.

BC, breast cancer; HR, hormone receptor; HER2, human epidermal growth factor receptor; m, metastatic; NCT, national clinical trial; PD-L1, programd death-lignd 1; TNBC, triple-negative breast cancer.

1. Sung H, et al. CA Cancer J Clin. 2021;71(3):209-249 2. National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Cancer Stat Facts: Female Breast Cancer Subtypes — Cancer Stat Facts. Available at https://seer.cancer.gov/statfacts/html/breast-subtypes.html. Accessed May 30, 2023. 3.Gilead Sciences Inc. Second Quarter 2023 Resource Book. August 3, 2023. Available at: https://s29.q4cdn.com/585078350/files/doc_financials/2023/q2/GILD-Q223-Resource-Book-10-August-2023.pdf